West Pharmaceutical Services (WST) experienced a strong rebound in Q3, despite various share activities from different investors and fund managers. Several parties have cut or sold their stake in WST, including XTX Topco Ltd, Baird Financial Group, Brown Advisory, and M&T Bank Corp, while others such as Epoch Investment Partners, Quantbot Technologies, Edgestream Partners, and Norges Bank have raised their stake. The company's stock rating was lowered to 'Hold' at Wall Street Zen, while it was maintained at Morgan Stanley with a target price of $285. The investors are presented with the opportunity to lead West Pharmaceutical Services. risk and lawsuit alerts were also reported. There are strong expectations on its valuation backed by bullish market momentum, and strong Q3 results. West WST welcomes Robert McMahon as its incoming Chief Financial Officer and its stock predictions remain positive. Various analyses continue to shape the company's investment narrative, especially the strong Q3 results and raised guidance. WST saw a rise in popularity after raising its 2025 guidance and beating Q3 expectations. However, caution was urged due to non-core weakness and injectable disruption risks. JPMorgan Chase & Co. notable sales of shares while the company launched a new prefillable syringe system and announced promising Q2 earnings. The stock is also touted as a potential hidden gem.
West Pharmaceutical Services WST News Analytics from Thu, 13 Feb 2025 08:00:00 GMT to Sat, 06 Dec 2025 12:48:32 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -1
